Bradwell et al. analyzed a large cohort of 325 NDMM patients and observed that those with an HLCr below or above median values (<0.018 or >93.5 for IgG MM, and <0.01 and >462 for IgA MM) displayed shorter progression-free survival (PFS). This evidence concerns the gene CD79A and Miyoshi myopathy.